307 related articles for article (PubMed ID: 15483106)
1. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
[TBL] [Abstract][Full Text] [Related]
2. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
Tarkun I; Cetinarslan B; Türemen E; Sahin T; Cantürk Z; Komsuoglu B
Eur J Endocrinol; 2005 Jul; 153(1):115-21. PubMed ID: 15994753
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
4. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
[TBL] [Abstract][Full Text] [Related]
7. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
[TBL] [Abstract][Full Text] [Related]
8. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
9. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
[TBL] [Abstract][Full Text] [Related]
10. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
Belli SH; Graffigna MN; Oneto A; Otero P; Schurman L; Levalle OA
Fertil Steril; 2004 Mar; 81(3):624-9. PubMed ID: 15037412
[TBL] [Abstract][Full Text] [Related]
14. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
Liao L; Tian YJ; Zhao JJ; Xin Y; Xing HY; Dong JJ
Chin Med J (Engl); 2011 Mar; 124(5):714-8. PubMed ID: 21518564
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
Adams JM; Taylor AE; Crowley WF; Hall JE
J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.
Ghazeeri G; Kutteh WH; Bryer-Ash M; Haas D; Ke RW
Fertil Steril; 2003 Mar; 79(3):562-6. PubMed ID: 12620440
[TBL] [Abstract][Full Text] [Related]
18. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome.
Mohsen IA
Gynecol Endocrinol; 2012 Apr; 28(4):269-72. PubMed ID: 21970545
[TBL] [Abstract][Full Text] [Related]
20. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
Legro RS; Zaino RJ; Demers LM; Kunselman AR; Gnatuk CL; Williams NI; Dodson WC
Am J Obstet Gynecol; 2007 Apr; 196(4):402.e1-10; discussion 402.e10-1. PubMed ID: 17403436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
